[Disorder of eating behavior and comorbid syndromes in obesity and methods of their correction].

Abstract

Eating behavior and comorbid syndromes were investigated in 40 women with obesity. A frequent combination of obesity with disorders of eating behavior, with emotional-personality, psychoautonomic and algesic disorders as well as with appearance of affective disorders during dietetic nutrition ("dietetic depression") required their correction. As a result of insufficiency of serotoninergic system of brain in pathogenesis of such disorders, fluoxetine (prozac)-a selective inhibitor of serotonine reuptake--was used for treatment of eating disorders. Heterogeneity in the structure of the obesity is shown. Disorders of eating behavior were combined with pronounced anxiety, depression, algesic and psychoautonomic syndromes. Therapy with prozac during 3 months in dose of 20 mg daily resulted in decrease of weight. Normalization of eating pattern, decrease of anxiety, depression, reaction to the external stimuli, increase of stress-resistance of patients, alterations in eating liking, decrease of severity of disorders comorbid to obesity were observed. A conclusion is made that prozac is indicated for patients in whom pathology of eating behavior plays a significant role in pathogenesis of obesity.

• Authors: T G Voznesenskaia, V A Safonova, N M Platonova
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 100 Issue 12 Pg. 49-52 ( 2000) ISSN: 1997-7298 [Print] Russia (Federation)
• Vernacular Title: Narushenie pishchevogo povedeniia i komorbidnye sindromy pri ozhirenii i metody ikh korrektsii.
• PMID: 11195539 (Publication Type: English Abstract, Journal Article)

Chemical References

• Serotonin Uptake Inhibitors
• Fluoxetine

Topics

• Adult
• Depressive Disorder (complications, diagnosis, drug therapy)
• Feeding Behavior (drug effects)
• Female
• Fluoxetine (pharmacology, therapeutic use)
• Humans
• Obesity (complications, drug therapy)
• Selective Serotonin Reuptake Inhibitors (pharmacology, therapeutic use)
• Severity of Illness Index
• Treatment Outcome